Navigation Links
ImaRx to Report Corporate Updates and 4Q07 Financial Results
Date:3/20/2008

of 1995. Such statements include but are not limited those related to our efforts to grow the marketplace for urokinase, our intent to reduce our operating expenses associated with our SonoLysis development and our belief that we will allow the Company to explore additional therapeutic applications for the product. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. Such risks and uncertainties include but are not limited to: sales of and demand for urokinase may decline, the FDA may not approve our future requests for urokinase lot releases or approval of expanded uses of urokinase beyond treatment of acute massive pulmonary emboli, we may not be able to complete definitive documentation with Microbix on the terms of our letter of intent, Microbix may not be able to perfect the manufacturing process or to secure approval from the FDA to manufacture urokinase, we may not be effective in our marketing efforts for urokinase, and we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of January 30, 2008, and the Company undertakes no duty to update this information. A more complete description of these risks can be found in the Company's filings with the Securities and Exchange Commission.

Contacts:

The Ruth Group

Sara Ephraim (investors)

646-536-7002

sephraim@theruthgroup.com

Jason Rando (media)

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
3. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
4. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
5. Vion Reports 2007 Fourth Quarter and Year-End Results
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
8. Warner Chilcott Reports the Death of Its Director James Andress
9. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
11. Unigene Restates Policy on Analyst Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 Adult stem ... therapies are biological, but not magical. However, ... to treat them as if they were magical. ... unsanctioned studies that constitute “stem cell tourism,” are ... approach to developing new regenerative medicine therapies. In ...
(Date:7/22/2014)... (PRWEB) July 23, 2014 The ... , The goal of the Symposium is ... spectrum of scientists working in the biomaterials field, ... that represent the most promising directions for ultimate ...     Provide faculty and government scientists with ...
(Date:7/22/2014)... a phylum so full of mean little creatures, the yellow-colored ... cruelty -- at least to crickets. Native to the southeastern ... predatory sort of parasite. It swoops onto the back of ... leaves its wicked brood to invade, kill and consume the ... be possible without the fly,s ability to find a cricket ...
(Date:7/22/2014)... metal nanoparticles in water with ultrasound and they,ll spin ... No one yet knows exactly. But researchers at the ... their speedand it,s fast. At up to 150,000 revolutions ... any nanoscale object submerged in liquid ever reported. , ... the possibility that they could be used not only ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2
... flow measurement and control provider, is pleased to ... new family of mass flow products designed to ... Built on a standard 1.125-inch wide platform with ... the B-Series provides a compact flow measurement and ...
... XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) ... for one week in accordance with its articles of association ... will take place at the Company, Building 3, Kiryat Weizmann ... p.m. Israel time on March 18, 2009.Any proxy votes received ...
... it has been awarded a 5-year, $17.8 million contract ... to lead a team of organizations in improving private ... member of the North American Free Trade Agreement and ... USAID programs support Mexican efforts to strengthen democratic ...
Cached Biology Technology:Brooks Instrument's New Mass Flow Controller Series Is Immune to Pressure and Temperature Fluctuations 2Brooks Instrument's New Mass Flow Controller Series Is Immune to Pressure and Temperature Fluctuations 3USAID Selects Abt Associates to Lead Team in Strengthening Mexico Private Sector Competitiveness 2
(Date:7/23/2014)... Protection Agency (EPA) today announced that environmental health ... Amherst School of Public Health and Health Sciences ... Achieve Results (STAR) grant to measure indoor air ... in subarctic North America to determine possible health ... culturally-relevant recommendations for mitigation. , Peltier, who will ...
(Date:7/23/2014)... New research from North Carolina State University shows that ... the southeastern United States. One factor is that researchers ... produced by the gloomy scale insect a significant ... leads to 200 times more adult gloomy scales on ... plant-eating insects like the gloomy scale in cities, and ...
(Date:7/23/2014)... of Antarctic fur seals, alongside decades of in-depth ... of climate change on a population of top-predators. ... findings show that the seals have significantly altered ... are associated with climate conditions. Despite a shift ... is not passing down through generations, leaving the ...
Breaking Biology News(10 mins):Studying impacts of indoor air pollution on tribal communities 2Studying impacts of indoor air pollution on tribal communities 3Urban heat boosts some pest populations 200-fold, killing red maples 2Urban heat boosts some pest populations 200-fold, killing red maples 3Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3
... because you don,t swallow the worm at the bottom of ... essential worminess of the potent Mexican liquor, according to scientists ... G,s Biodiversity Institute of Ontario (BIO) have discovered that mescal ... the famously tasty "worm" that many avoid consuming. Their findings ...
... Infectious Diseases (NIAID), part of the National Institutes of ... to Tulane University for its ongoing efforts to treat ... that threatens hundreds of thousands of people annually in ... threat. The contract will include collaboration between Tulane; ...
... Miami have analyzed images based on Synthetic Aperture Radar ... on January 12. The images reveal surprising new details. ... ALOS satellite and made available to the scientific community ... and GEO, the Group of Earth Observation, an umbrella ...
Cached Biology News:Mescal 'worm' test shows DNA leaks into preservatives 2Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2New international satellite observations help assess future earthquake risk in Haiti 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
Biology Products: